Company Description

DomainOne Therapeutics is redefining the paradigm for targeting TGF-β, a key regulator of fibrosis, inflammation, and cancer by developing small molecule antagonists of Thrombospondin-1 (TSP-1) a disease-relevant regulator of TGF-β activation at sites of inflammation. Their first-in-class small molecule antagonists are designed to disrupt fibrosis at its source, to prevent excessive tissue scarring while maintaining the body’s healthy repair functions.